{"id":62269,"date":"2025-11-28T01:02:04","date_gmt":"2025-11-28T00:02:04","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\/"},"modified":"2025-11-28T01:02:04","modified_gmt":"2025-11-28T00:02:04","slug":"celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\/","title":{"rendered":"Celltrion receives Health Canada approval for Eydenzelt\u00ae, a biosimilar referencing Eylea\u00ae (aflibercept 2mg)"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<i>Eydenzelt<\/i><sup>\u00ae<\/sup><i> a biosimilar referencing Eylea<\/i><sup>\u00ae<\/sup>,<i> receives a Notice of Compliance from Health Canada (aflibercept 2mg)<\/i>\n<\/li>\n<li>\n<i>The approval is based on the totality of evidence, including analytical, nonclinical, and clinical data from global Phase III studies demonstrating Eydenzelt is similar in efficacy and safety for all approved indications<\/i>\n<\/li>\n<li>\n<i>Celltrion expands its biosimilars portfolio into ophthalmology reinforcing commitment to broader patient access in Canada<\/i>\n<\/li>\n<\/ul>\n<p>TORONTO, Ontario&#8211;(BUSINESS WIRE)&#8211;Celltrion, Inc. today announced that Health Canada has approved Eydenzelt<sup>\u00ae<\/sup>, a biosimilar referencing Eylea<sup>\u00ae<\/sup> (aflibercept 2mg), in both vial and pre-filled syringe format, for treatment of all indications approved for Eylea.<sup>1<\/sup>\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20251119058907\/en\/2650410\/5\/Celltrion-CI_1.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251119058907\/en\/2650410\/22\/Celltrion-CI_1.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20251119058907\/en\/2650410\/5\/Celltrion-CI_1.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251119058907\/en\/2650410\/21\/Celltrion-CI_1.jpg\"><\/a><\/p>\n<p>\n\u201cToday\u2019s approval lays a solid foundation for Celltrion\u2019s expansion into the Canadian ophthalmology market and represents a significant milestone in diversifying the company\u2019s portfolio,\u201d said Jungyong Shin, Managing Director at Celltrion Healthcare Canada. \u201cBuilding on this milestone, Celltrion will further strengthen its presence in Canada by leveraging its advanced manufacturing capabilities and R&amp;D expertise to improve patient access to high-quality biosimilar treatments.\u201d\n<\/p>\n<p>\nThe Health Canada approval is based on totality of evidence including analytical, nonclinical, and clinical data. A global, randomized, double-masked, parallel-group, multicenter Phase III study evaluated the efficacy, safety, pharmacokinetics, and immunogenicity of Eydenzelt compared to Eylea in patients with approved indications. The 52-week trial included 348 patients with diabetic macular edema (DME). The primary endpoint was the change in best corrected visual acuity measured at week 8 from baseline, comparing Eydenzelt and Eylea. Results of the study showed that Eydenzelt met the predefined equivalence criteria, and secondary endpoints of efficacy, safety, and immunogenicity also showed trends similar to Eylea.<sup>2<\/sup>\n<\/p>\n<p>\nEydenzelt is Celltrion&#8217;s first Health Canada-approved biologic product in ophthalmology. Eydenzelt was also approved by the European Commission (EC) and the U.S. Food and Drug Administration (FDA) in February and October 2025, respectively.\n<\/p>\n<p>\n<b>Notes to Editors:<\/b>\n<\/p>\n<p>\n<b>About Eydenzelt<sup>\u00ae<\/sup><\/b>\n<\/p>\n<p>\nEydenzelt<sup>\u00ae<\/sup> is a vascular endothelial growth factor (VEGF) inhibitor referencing Eylea<sup>\u00ae <\/sup>(aflibercept). Eydenzelt is approved based on a comprehensive data confirming the therapeutic equivalence Eylea. In Canada Eydenzelt is approved for the treatment of all indications approved for Eylea.<sup>1<\/sup>\n<\/p>\n<p>\n<b>About Celltrion Inc.<\/b>\n<\/p>\n<p>\nCelltrion is a leading biopharmaceutical company that specialises in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people&#8217;s lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world&#8217;s first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, haematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.celltrion.com%2Fen-us&amp;esheet=54361332&amp;newsitemid=20251119058907&amp;lan=en-US&amp;anchor=www.celltrion.com%2Fen-us&amp;index=1&amp;md5=8010c7344b35e5d08708d61252afe444\" rel=\"nofollow\" shape=\"rect\">www.celltrion.com\/en-us<\/a> and stay updated with our latest news and events on our social media &#8211; <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fcelltrioninc%2F%3FviewAsMember%3Dtrue&amp;esheet=54361332&amp;newsitemid=20251119058907&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=2&amp;md5=af034ec679cb396e170ca93d61300aaa\" rel=\"nofollow\" shape=\"rect\">LinkedIn<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fcelltrion_global%2F&amp;esheet=54361332&amp;newsitemid=20251119058907&amp;lan=en-US&amp;anchor=Instagram&amp;index=3&amp;md5=beefe837c9be59bb0dab99dd8b5ba4ec\" rel=\"nofollow\" shape=\"rect\">Instagram<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FCelltrioninc&amp;esheet=54361332&amp;newsitemid=20251119058907&amp;lan=en-US&amp;anchor=X&amp;index=4&amp;md5=3523238a348203fdf6cf5af8c3e693f2\" rel=\"nofollow\" shape=\"rect\">X<\/a>, and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2Fcelltrionglobal%2F&amp;esheet=54361332&amp;newsitemid=20251119058907&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=755018d4d7a8c886ca3f3c03eea5006e\" rel=\"nofollow\" shape=\"rect\">Facebook<\/a>.\n<\/p>\n<p>\n<b>About Celltrion Healthcare Canada Limited<\/b>\n<\/p>\n<p>\nCelltrion Healthcare Canada is committed to delivering innovative and affordable medications to promote patients\u2019 access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with Health Canada regulations. With the approval of Eydenzelt<sup>\u00ae<\/sup>, Celltrion now has ten products across eight biosimilars approved by Health Canada: Remdantry\u2122\/ Remsima<sup>\u00ae<\/sup> SC (infliximab), Yuflyma<sup>\u00ae<\/sup> (adalimumab), Vegzelma<sup>\u00ae<\/sup> (bevacizumab), SteQeyma<sup>\u00ae<\/sup> (ustekinumab), Omlyclo<sup>\u00ae <\/sup>(omalizumab), Stoboclo<sup>\u00ae <\/sup>\/ Osenvelt<sup>\u00ae<\/sup> (denosumab), Avtozma<sup>\u2122<\/sup> (tocilizumab) and Eydenzelt<sup>\u00ae <\/sup>(aflibercept 2mg). For more information, please visit: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.celltrionhealthcare.ca%2F&amp;esheet=54361332&amp;newsitemid=20251119058907&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.celltrionhealthcare.ca&amp;index=6&amp;md5=ff0ce4697db60e5b54d19c3447c055e7\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.celltrionhealthcare.ca<\/a>\n<\/p>\n<p>\nEydenzelt<sup>\u00ae <\/sup>is trademarks of Celltrion, Inc. and are used under license.<br \/>\n<br \/>Eylea<sup>\u00ae<\/sup> is registered trademarks of Bayer Inc.\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n____________________\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<sup>1<\/sup> Eydenzelt Product Monograph. Celltrion Inc. November 2025. Product information from Health Canada<br \/>\n<br \/><sup>2<\/sup> Brown M et al. Long-Term Efficacy and Safety of CT-P42 in Patients with Diabetic Macular Edema: 52-Week Results from a Phase 3 Randomized Clinical Trial. Ophthalmol Ther. 2025 Nov;14:2769-2783. doi: 10.1007\/s40123-025-01197-w. Epub 2025 Aug 29. Available at: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs40123-025-01197-w&amp;esheet=54361332&amp;newsitemid=20251119058907&amp;lan=en-US&amp;anchor=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs40123-025-01197-w&amp;index=7&amp;md5=abc4619a3c5d1a1879126def39740070\" rel=\"nofollow\" shape=\"rect\">https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01197-w<\/a> [Last accessed Nov 2025]\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media Relations Contact<br \/>\n<br \/><\/b><a target=\"_blank\" href=\"&#x6d;&#97;&#105;l&#x74;&#x6f;&#58;i&#x6e;&#x66;&#111;_C&#x41;&#64;&#99;e&#x6c;&#x6c;&#116;r&#x69;&#x6f;&#110;&#104;c&#x2e;&#x63;&#111;m\" rel=\"nofollow\" shape=\"rect\">&#x69;n&#x66;&#111;&#x5f;&#67;A&#x40;c&#x65;&#108;&#x6c;&#116;r&#x69;&#111;&#x6e;&#104;c&#x2e;c&#x6f;&#109;<\/a><br \/><a target=\"_blank\" href=\"&#109;&#97;&#x69;l&#116;&#x6f;&#x3a;J&#111;&#x65;&#x79;&#46;&#66;&#x72;&#x6f;g&#110;&#x6f;&#x40;c&#101;&#x6c;&#x6c;t&#114;&#x69;o&#110;&#104;&#x63;&#46;&#99;&#x6f;&#x6d;\" rel=\"nofollow\" shape=\"rect\">Joey&#46;Brogno&#64;celltrionhc&#46;&#99;&#111;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Eydenzelt\u00ae a biosimilar referencing Eylea\u00ae, receives a Notice of Compliance from Health Canada (aflibercept 2mg) The approval is based on the totality of evidence, including analytical, nonclinical, and clinical data from global Phase III studies demonstrating Eydenzelt is similar in efficacy and safety for all approved indications Celltrion expands its biosimilars portfolio into ophthalmology reinforcing &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62269","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Celltrion receives Health Canada approval for Eydenzelt\u00ae, a biosimilar referencing Eylea\u00ae (aflibercept 2mg) - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celltrion receives Health Canada approval for Eydenzelt\u00ae, a biosimilar referencing Eylea\u00ae (aflibercept 2mg) - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Eydenzelt\u00ae a biosimilar referencing Eylea\u00ae, receives a Notice of Compliance from Health Canada (aflibercept 2mg) The approval is based on the totality of evidence, including analytical, nonclinical, and clinical data from global Phase III studies demonstrating Eydenzelt is similar in efficacy and safety for all approved indications Celltrion expands its biosimilars portfolio into ophthalmology reinforcing ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-28T00:02:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251119058907\/en\/2650410\/22\/Celltrion-CI_1.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Celltrion receives Health Canada approval for Eydenzelt\u00ae, a biosimilar referencing Eylea\u00ae (aflibercept 2mg)\",\"datePublished\":\"2025-11-28T00:02:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\\\/\"},\"wordCount\":647,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251119058907\\\/en\\\/2650410\\\/22\\\/Celltrion-CI_1.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\\\/\",\"name\":\"Celltrion receives Health Canada approval for Eydenzelt\u00ae, a biosimilar referencing Eylea\u00ae (aflibercept 2mg) - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251119058907\\\/en\\\/2650410\\\/22\\\/Celltrion-CI_1.jpg\",\"datePublished\":\"2025-11-28T00:02:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251119058907\\\/en\\\/2650410\\\/22\\\/Celltrion-CI_1.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251119058907\\\/en\\\/2650410\\\/22\\\/Celltrion-CI_1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celltrion receives Health Canada approval for Eydenzelt\u00ae, a biosimilar referencing Eylea\u00ae (aflibercept 2mg)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Celltrion receives Health Canada approval for Eydenzelt\u00ae, a biosimilar referencing Eylea\u00ae (aflibercept 2mg) - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\/","og_locale":"en_US","og_type":"article","og_title":"Celltrion receives Health Canada approval for Eydenzelt\u00ae, a biosimilar referencing Eylea\u00ae (aflibercept 2mg) - Pharma Trend","og_description":"Eydenzelt\u00ae a biosimilar referencing Eylea\u00ae, receives a Notice of Compliance from Health Canada (aflibercept 2mg) The approval is based on the totality of evidence, including analytical, nonclinical, and clinical data from global Phase III studies demonstrating Eydenzelt is similar in efficacy and safety for all approved indications Celltrion expands its biosimilars portfolio into ophthalmology reinforcing ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\/","og_site_name":"Pharma Trend","article_published_time":"2025-11-28T00:02:04+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251119058907\/en\/2650410\/22\/Celltrion-CI_1.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Celltrion receives Health Canada approval for Eydenzelt\u00ae, a biosimilar referencing Eylea\u00ae (aflibercept 2mg)","datePublished":"2025-11-28T00:02:04+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\/"},"wordCount":647,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251119058907\/en\/2650410\/22\/Celltrion-CI_1.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\/","url":"https:\/\/pharma-trend.com\/en\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\/","name":"Celltrion receives Health Canada approval for Eydenzelt\u00ae, a biosimilar referencing Eylea\u00ae (aflibercept 2mg) - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251119058907\/en\/2650410\/22\/Celltrion-CI_1.jpg","datePublished":"2025-11-28T00:02:04+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251119058907\/en\/2650410\/22\/Celltrion-CI_1.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251119058907\/en\/2650410\/22\/Celltrion-CI_1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2mg\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Celltrion receives Health Canada approval for Eydenzelt\u00ae, a biosimilar referencing Eylea\u00ae (aflibercept 2mg)"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62269","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62269"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62269\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62269"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62269"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62269"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}